Metropolis says may outperform FY21 EBITDA margins, as led by recovery of non-COVID testing

Metropolis says may outperform FY21 EBITDA margins, as led by recovery of non-COVID testing COVID-19 testing contributed about 19 percent to Q1 FY22 revenue, but this stream is now declining and other tests will drive growth in the rest of the fiscal year, the MD of Metropolis Healthcare says

No comments:

Post a Comment